[{"id":"17c029cc-5449-4ba9-99f6-13ebaefd3227","acronym":"EVOLVE 1","url":"https://clinicaltrials.gov/study/NCT07075016","created_at":"2025-07-26T13:34:40.222Z","updated_at":"2025-07-26T13:34:40.222Z","phase":"Phase 3","brief_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","source_id_and_acronym":"NCT07075016 - EVOLVE 1","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-07-20"},{"id":"fc5b6895-f7f7-4459-b71c-62a35c47f883","acronym":"ProvIDHe","url":"https://clinicaltrials.gov/study/NCT05876754","created_at":"2023-05-25T15:05:46.429Z","updated_at":"2025-02-25T15:20:32.101Z","phase":"Phase 3","brief_title":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT05876754 - ProvIDHe","lead_sponsor":"Servier Affaires Médicales","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-10"},{"id":"51b4bfec-34ee-4216-99bf-f5a89c3e2090","acronym":"","url":"https://clinicaltrials.gov/study/NCT04056910","created_at":"2021-01-18T19:53:13.460Z","updated_at":"2025-02-25T14:28:34.351Z","phase":"Phase 2","brief_title":"Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors","source_id_and_acronym":"NCT04056910","lead_sponsor":"Jason J. Luke, MD","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tibsovo (ivosidenib)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 11/13/2023","primary_completion_date":" 11/13/2023","study_txt":" Completion: 11/13/2023","study_completion_date":" 11/13/2023","last_update_posted":"2025-02-06"},{"id":"a154a323-d6ef-4152-926e-c4ab1ae75b5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756777","created_at":"2023-03-06T15:01:58.629Z","updated_at":"2025-02-25T15:36:05.770Z","phase":"Phase 1","brief_title":"A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05756777","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation","tags":["FLT3 • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-11-12"},{"id":"8e4c392a-1d29-432d-a4da-6bb8e1258676","acronym":"AG120-221-C-001","url":"https://clinicaltrials.gov/study/NCT02632708","created_at":"2021-01-17T17:12:58.212Z","updated_at":"2025-02-25T14:36:02.501Z","phase":"Phase 1","brief_title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","source_id_and_acronym":"NCT02632708 - AG120-221-C-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Tibsovo (ivosidenib) • daunorubicin • Idhifa (enasidenib) • idarubicin hydrochloride • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/31/2015","start_date":" 12/31/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-07-25"},{"id":"ab92a282-919a-4023-ac7a-0869d1798034","acronym":"NCI-2021-00893","url":"https://clinicaltrials.gov/study/NCT04774393","created_at":"2021-03-01T14:52:29.975Z","updated_at":"2024-07-02T16:34:59.147Z","phase":"Phase 1/2","brief_title":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04774393 - NCI-2021-00893","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-06-04"},{"id":"94267f47-1a52-4bba-b2c5-458f4dbd292b","acronym":"NCI-2018-00921","url":"https://clinicaltrials.gov/study/NCT03471260","created_at":"2021-01-18T17:06:25.544Z","updated_at":"2024-07-02T16:35:06.479Z","phase":"Phase 1/2","brief_title":"Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies","source_id_and_acronym":"NCT03471260 - NCI-2018-00921","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 03/19/2018","start_date":" 03/19/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-02"},{"id":"67354b23-56a9-47e7-b780-039f1a9df99b","acronym":"IDIOME-STUDY","url":"https://clinicaltrials.gov/study/NCT03503409","created_at":"2021-01-18T17:14:52.332Z","updated_at":"2024-07-02T16:35:08.621Z","phase":"Phase 2","brief_title":"IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome","source_id_and_acronym":"NCT03503409 - IDIOME-STUDY","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/02/2025","study_completion_date":" 04/02/2025","last_update_posted":"2024-04-19"},{"id":"8458f7b4-ba3b-4835-b691-1de379b3d9f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05921760","created_at":"2023-06-27T14:08:24.970Z","updated_at":"2024-07-02T16:35:10.760Z","phase":"Phase 1/2","brief_title":"Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma","source_id_and_acronym":"NCT05921760","lead_sponsor":"Servier Bio-Innovation LLC","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132C • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132C • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 10/23/2023","start_date":" 10/23/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-09"},{"id":"ddfe20df-1f45-4bde-9f8e-bac111609114","acronym":"AG120-C-001","url":"https://clinicaltrials.gov/study/NCT02074839","created_at":"2021-01-17T17:36:59.974Z","updated_at":"2024-07-02T16:35:11.311Z","phase":"Phase 1","brief_title":"Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation","source_id_and_acronym":"NCT02074839 - AG120-C-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 291","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-04-05"},{"id":"fca31f0b-440e-4612-89e8-eec4d5639d00","acronym":"AGILE","url":"https://clinicaltrials.gov/study/NCT03173248","created_at":"2021-01-18T15:38:46.635Z","updated_at":"2024-07-02T16:35:11.233Z","phase":"Phase 3","brief_title":"Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation","source_id_and_acronym":"NCT03173248 - AGILE","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 06/26/2017","start_date":" 06/26/2017","primary_txt":" Primary completion: 03/18/2021","primary_completion_date":" 03/18/2021","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-05"},{"id":"09b338fd-9282-46d6-9d99-4a47a5014ccb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06081829","created_at":"2023-10-14T01:13:09.299Z","updated_at":"2024-07-02T16:35:14.249Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation","source_id_and_acronym":"NCT06081829","lead_sponsor":"Servier","biomarkers":" IDH1","pipe":"","alterations":" ","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-03-18"},{"id":"6053286c-83b6-47bb-9279-55103c8270d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04493164","created_at":"2021-01-18T21:35:03.148Z","updated_at":"2024-07-02T16:35:14.734Z","phase":"Phase 2","brief_title":"CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT04493164","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"95731383-c806-4e36-ace1-c94c54c5626b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03564821","created_at":"2021-01-18T17:32:33.230Z","updated_at":"2024-07-02T16:35:15.543Z","phase":"Phase 1","brief_title":"IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT03564821","lead_sponsor":"Massachusetts General Hospital","biomarkers":" IDH1 • HLA-B","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132","tags":["IDH1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 01/16/2019","start_date":" 01/16/2019","primary_txt":" Primary completion: 05/22/2022","primary_completion_date":" 05/22/2022","study_txt":" Completion: 06/06/2023","study_completion_date":" 06/06/2023","last_update_posted":"2024-03-08"},{"id":"259e072d-8792-4679-9b6b-60d1a376f946","acronym":"I-DATA","url":"https://clinicaltrials.gov/study/NCT05401097","created_at":"2022-06-02T16:58:56.588Z","updated_at":"2024-07-02T16:35:16.613Z","phase":"Phase 2","brief_title":"IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)","source_id_and_acronym":"NCT05401097 - I-DATA","lead_sponsor":"Alice Mims","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-03-04"},{"id":"caba8d6b-3a99-4cf4-a5f0-d1c3cfbe3575","acronym":"","url":"https://clinicaltrials.gov/study/NCT03343197","created_at":"2021-01-18T16:30:40.675Z","updated_at":"2024-07-02T16:35:17.668Z","phase":"Phase 1","brief_title":"Study of AG-120 and AG-881 in Subjects With Low Grade Glioma","source_id_and_acronym":"NCT03343197","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" ATRX mutation • IDH1 R132H • IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Voranigo (vorasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 08/02/2019","primary_completion_date":" 08/02/2019","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-02-26"},{"id":"1d1beaaf-4116-4a22-9f63-9b6fceba4d8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02073994","created_at":"2021-01-17T17:13:56.320Z","updated_at":"2024-07-02T16:35:19.516Z","phase":"Phase 1","brief_title":"Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation","source_id_and_acronym":"NCT02073994","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1","pipe":"","alterations":" ","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Completed","enrollment":" Enrollment 174","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2024","study_completion_date":" 01/04/2024","last_update_posted":"2024-02-13"},{"id":"7d4d4048-18e5-40d0-ab1f-5614ad531ff9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05907057","created_at":"2023-07-17T15:10:21.429Z","updated_at":"2024-07-02T16:35:28.651Z","phase":"Phase 3","brief_title":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","source_id_and_acronym":"NCT05907057","lead_sponsor":"Servier Affaires Médicales","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 06/14/2023","start_date":" 06/14/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2023-11-20"},{"id":"6c356fe9-c43c-4dcb-800e-d509283b31da","acronym":"","url":"https://clinicaltrials.gov/study/NCT04278781","created_at":"2021-01-18T20:46:42.245Z","updated_at":"2024-07-02T16:35:39.443Z","phase":"Phase 2","brief_title":"AG-120 in People With IDH1 Mutant Chondrosarcoma","source_id_and_acronym":"NCT04278781","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" IDH1","pipe":"","alterations":" ","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-08-21"},{"id":"da0aba2e-1cdd-4bb3-b3f5-17acd4cb3848","acronym":"","url":"https://clinicaltrials.gov/study/NCT04250051","created_at":"2021-01-18T20:39:12.207Z","updated_at":"2024-07-02T16:35:48.026Z","phase":"Phase 1","brief_title":"Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04250051","lead_sponsor":"Northwestern University","biomarkers":" IDH1 • UGT1A1","pipe":" | ","alterations":" IDH1 R132 • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH1 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132 • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Tibsovo (ivosidenib) • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-05-15"},{"id":"19c4df63-c1d0-4fe1-a179-ba050e9a7b85","acronym":"","url":"https://clinicaltrials.gov/study/NCT04955938","created_at":"2021-07-09T12:57:16.797Z","updated_at":"2024-07-02T16:35:49.331Z","phase":"Phase 1","brief_title":"A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms","source_id_and_acronym":"NCT04955938","lead_sponsor":"University of Chicago","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Idhifa (enasidenib) • Inrebic (fedratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-04-28"},{"id":"6673509a-4aa3-4ef3-8695-1ef21d9d0375","acronym":"","url":"https://clinicaltrials.gov/study/NCT04176393","created_at":"2021-07-16T16:52:33.230Z","updated_at":"2024-07-02T16:35:55.767Z","phase":"Phase 1","brief_title":"A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation","source_id_and_acronym":"NCT04176393","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 11/12/2019","start_date":" 11/12/2019","primary_txt":" Primary completion: 02/18/2021","primary_completion_date":" 02/18/2021","study_txt":" Completion: 01/18/2023","study_completion_date":" 01/18/2023","last_update_posted":"2023-02-13"},{"id":"b6751a5d-2b30-4afb-9a75-5fbf38411c4e","acronym":"ClarIDHy","url":"https://clinicaltrials.gov/study/NCT02989857","created_at":"2021-01-17T17:13:55.238Z","updated_at":"2024-07-02T16:35:57.587Z","phase":"Phase 3","brief_title":"Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)","source_id_and_acronym":"NCT02989857 - ClarIDHy","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132C • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132C • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Completed","enrollment":" Enrollment 187","initiation":"Initiation: 02/20/2017","start_date":" 02/20/2017","primary_txt":" Primary completion: 01/31/2019","primary_completion_date":" 01/31/2019","study_txt":" Completion: 05/17/2021","study_completion_date":" 05/17/2021","last_update_posted":"2023-01-16"},{"id":"f514e125-fc12-410e-8afb-782e274842a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04655391","created_at":"2021-01-19T20:41:28.630Z","updated_at":"2024-07-02T16:36:09.137Z","phase":"Phase 1b","brief_title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04655391","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • ABL1 • BCR • IDH1 • AXL","pipe":" | ","alterations":" IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836","tags":["FLT3 • ABL1 • BCR • IDH1 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • bosutinib • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/25/2022","start_date":" 06/25/2022","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-06-09"}]